杭州泰格医药科技股份有限公司 章程修订对照表 | 序号 | 原条款 | 修订后条款 | | --- | --- | --- | | | 第一条 为维护杭州泰格医药科技股份有限 《中华人民共和国证券法》（以下简称《证券 | 简称《公司法》）、《中华人民共和国证券 | | | | 第一条 为维护杭州泰格医药科技股份有 限公司（以下简称"公司"）、股东、职工 | | | 公司（以下简称"公司"）、股东和债权人的 | 和债权人的合法权益，规范公司的组织和行 | | | 合法权益，规范公司的组织和行为，根据《中 | 为，根据《中华人民共和国公司法》（以下 | | | 华人民共和国公司法》（以下简称《公司法》）、 | | | 1 | 法》）、《境内企业境外发行证券和上市管理 | 法》（以下简称《证券法》）、《境内企业 | | | 试行办法》（以下简称《境外上市管理办法》）、 | 境外发行证券和上市管理试行办法》（以下 | | | 《香港联合交易所有限公司证券上市规则》 | 简称《境外上市管理办法》）、《香港联合 | | | （以下简称《香港上市规则》）、《上市公司 | 交易所有限公司证券上市规则》（以下简称 | | | ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）038 号 杭州泰格医药科技股份有限公司 2025 年第一次临时股东会决议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 一、会议召开情况 1、会议召开时间 现场会议召开时间为：2025年9月29日（星期一）下午15：00 网络投票时间：2025年9月29日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月29日上午9： 15—9：25，9：30—11：30和下午13：00—15：00；通过深圳证券交易所互联网投票系统 进行网络投票的具体时间为2025年9月29日上午9：15至2025年9月29日下午15：00的任意时 间。 2、现场会议召开地点：杭州市滨江区聚工路19号盛大科技园A座18楼会议室 3、会议方式：本次股东会采取现场投票和网络投票相结合的方式 4、召集人：杭州泰格医药科技股份有限公司董事会 5、现场会议主持人：公司董事长叶小平先生 6、本次股东会会议的召集、召开与表决程序符合《公司法》、《上市公司股东会规则》、 《深圳证券交易所创业板股票上市规 ...

北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 嘉 源 律师事务所 JIA YUAN LAW OFFICES 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 关于杭州泰格医药科技股份有限公司 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:杭州泰格医药科技股份有限公司 北京市嘉源律师事务所 源在到前景 - Pr A YUAN LAW OFFICES 2025 年第一次临时股东会的 法律意见书 嘉源(2025)-04-725 受杭州泰格医药科技股份有限公司(以下简称"公司")委托,北京市嘉源 律师事务所(以下简称"本所")指派律师出席公司 2025年第一次临时股东会 (以下简称"本次股东会"),并依据《中华人民共和国公司法》(以下简称"《公 司法》"）、《上市公司股东会规则》(以下简称"《股东会规则》")、《杭 州泰格医药科技股份有限公司章程》(以下简称"《公司章程》")及《杭州泰 格医药科技股份有限公司股东会议事规则》(以下简称 ...

一、质押变动的基本情况 证券代码：300347 证券简称：泰格医药 公告编码（2025）040 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东部分股份回购并解除质押的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份回购并解除质押业务，具体内容如 下： | 曹晓春 | 51,314,174 | 5.96% | 22,600,000 | 20,000,000 | 38.98% | 2.32% | 20,000,000 | 100% | 18,746,330 | 59.87% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 叶小平 | 177,239,541 | 20.58% | - | - | - | - | - | - | 132,929,656 | 75% | | 合计 | 228,553,715 | 26.54% ...

Company Overview - Tigermed (stock code: 300347.SZ/3347.HK) is an integrated biopharmaceutical research and development service platform providing one-stop innovative R&D services and solutions for the global pharmaceutical and medical device industries [2] - Over the past 20 years, the company has collaborated with more than 3,600 partners, creating an innovative ecosystem that empowers the entire industry chain [2] - Tigermed has established over 180 offices and branches globally, employing more than 10,000 professionals across dozens of countries on five continents [2] - The company holds the highest MSCI ESG rating of AAA, a score of 60 on the S&P CSA ESG questionnaire, a B rating (management level) on the CDP climate change questionnaire, and maintains an AAA rating from the Shenzhen Stock Exchange National Index ESG [2] Compliance and Governance - Tigermed has built a compliance governance system covering the entire value chain, with a compliance and ESG committee under the board of directors, directly led by the director and general manager [3] - The company has established a systematic compliance risk management process, with specialized compliance groups regularly identifying, assessing, and responding to operational risks [3] - A multi-level supervision and risk identification mechanism is in place, covering headquarters, subsidiaries, and business departments, to ensure compliance and operational stability [3] Anti-Corruption and Data Security - The company has implemented a comprehensive anti-corruption and anti-bribery policy, with plans for company-wide anti-corruption training in 2024 [4] - Suppliers are required to sign a "Supplier Code of Conduct" and "Anti-Bribery and Anti-Corruption Commitment" during the onboarding process to ensure awareness of the company's policies [4] - Tigermed is continuously optimizing its data security management system, with measures to enhance network security, data lifecycle management, and information access control [4] - The company holds an ISO 27001:2013 information security management system certification, and three core business systems have passed the national information security level protection tier three certification [4] Intellectual Property Management - Tigermed views intellectual property as a crucial competitive advantage, having established various management policies and training programs related to intellectual property compliance [5] - The company is actively planning its intellectual property strategy and aims to achieve GB/T 29490-2023 intellectual property compliance management system certification in 2024 [5] Expert Commentary - In 2024, Tigermed will embed compliance objectives into executive assessments, with anti-corruption training covering all employees and 80% of global business (excluding listed subsidiaries) completing anti-corruption audits [5] - The requirement for suppliers to sign the "Anti-Bribery Commitment" ensures adherence to legal and ethical standards [5]

Core Viewpoint - Pharmaceutical stocks are under pressure following the announcement of new tariffs on imported pharmaceutical products by U.S. President Trump, which could significantly impact the industry [1] Group 1: Stock Performance - Companies such as 科济药业-B (02171) saw a decline of 5.11%, trading at 18.37 HKD [1] - 康宁杰瑞制药-B (09966) dropped by 3.48%, with a trading price of 12.22 HKD [1] - 维亚生物 (01873) fell by 3.52%, now priced at 2.47 HKD [1] - 泰格医药 (300347) (03347) decreased by 3.1%, trading at 45.6 HKD [1] Group 2: Tariff Announcement - Starting October 1, the U.S. will impose a 100% tariff on all brands and patented pharmaceutical products [1] - Trump indicated that these tariffs will not apply to companies that build factories in the U.S., defining such facilities as "under construction" [1] Group 3: Policy Context - Trump's administration has focused on "lowering drug prices" and "supply chain repatriation" as key themes in its policies affecting the pharmaceutical industry this year [1]

格隆汇9月26日｜港股市场药品股普跌，其中，康龙化成(300759)、恒瑞医药(600276)、百济神州跌超 3%，药明生物、泰格医药(300347)、康方生物等跌超2%。当地时间9月25日，美国总统特朗普宣布，自 10月1日起，美国将对多类进口产品实施新一轮高额关税，其中对任何品牌或专利的医药产品征收100% 的关税。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

Financial Performance - For the six months ended June 30, 2025, the company's operating revenue was RMB 3,250.4 million, a decrease of 3.2% compared to RMB 3,358.2 million for the same period in 2024[8]. - Gross profit for the same period was RMB 978.0 million, down 26.6% from RMB 1,333.0 million in 2024[8]. - Net profit attributable to the company's owners was RMB 383.3 million, a decline of 22.2% from RMB 492.8 million in the previous year[8]. - The net profit attributable to shareholders after excluding non-recurring gains and losses was RMB 210.7 million, a significant drop of 67.1% from RMB 640.3 million in 2024[8]. - The gross profit margin decreased to 30.1% from 39.7%, representing a decline of 9.6 percentage points[8]. - The net profit margin attributable to the company's owners was 11.8%, down from 14.7%, a decrease of 2.9 percentage points[8]. - The company's operating costs increased by 12.2% to RMB 2,272.5 million compared to RMB 2,025.2 million in 2024, with direct labor costs rising to 37.9% of revenue[49]. - The company's net profit for the period decreased by 34.9% to RMB 362.8 million, while profit attributable to shareholders fell by 22.2% to RMB 383.3 million[63]. Clinical Development and Innovation - In the first half of 2025, 38 Class 1 new drugs were approved by NMPA, the highest number for the same period in history[14]. - The number of innovative drug clinical trials reached 1,001, with a total of 1,858 trials reported in 2024[14]. - China contributed to over 50% of the pipeline for 18 out of the top 20 global drug targets, indicating a strong position in global drug development[14]. - The company anticipates that the pricing of Chinese innovative drug assets will align with global market standards as the quality of development reaches world-leading levels[15]. - The demand for clinical research outsourcing services has rebounded, with increased early inquiry activity from clients since 2025[22]. - The biopharmaceutical industry is transitioning from "scale expansion" to "value creation," entering a high-quality innovation phase[23]. - New technologies such as AI and decentralized clinical trials are significantly improving research efficiency and quality while reducing costs[24]. - The company has established integrated R&D service platforms for pharmaceuticals and medical devices, covering the entire R&D lifecycle from drug discovery to post-market studies[104]. Licensing and Market Expansion - In the first half of 2025, domestic companies achieved upfront payments of $2.784 billion in overseas licensing transactions, a year-on-year increase of 211%, with a potential total amount reaching $61.718 billion, up 140%[17]. - The number of overseas licensing transactions reached 82, representing a year-on-year growth of 75%[17]. - The total amount of overseas licensing transactions for Chinese innovative drugs continues to rise, indicating recognition of China's biotech assets and R&D capabilities by foreign pharmaceutical companies[17]. - The active licensing transactions and improved capital market liquidity are expected to drive long-term growth in clinical demand[22]. - The Chinese innovative drug market is projected to benefit from increasing domestic demand and the development of emerging markets such as Southeast Asia and Africa[24]. Workforce and Operational Capacity - As of June 30, 2025, the company has a total workforce of 10,251 employees across 33 countries, with over 1,000 clinical research associates (CRA) and 3,700 clinical research coordinators (CRC)[33]. - The company has expanded its workforce in the U.S. to nearly 200 employees, covering 68 cities across 27 states, with over 40 ongoing clinical trials[28]. - Following the acquisition of Micron Inc. in Japan, the company now has over 200 employees in Japan, enhancing its capabilities in clinical operations and medical imaging services[28]. - The company has established a comprehensive cooperation network with over 1,400 clinical trial institutions in China, enhancing management and efficiency through strategic partnerships[107]. Financial Management and Investments - The company's investment income increased by 229.6% year-on-year to RMB 233.0 million, primarily due to the share of profits from associates rising by 277.3% to RMB 166.4 million[58]. - The net cash inflow from investing activities improved significantly to RMB 45.9 million, compared to a net cash outflow of RMB 4,621.8 million in the same period last year[69]. - The company is a strategic investor in 195 innovative companies in the healthcare sector and a limited partner in 54 specialized investment funds as of June 30, 2025[83]. - The company realized gains of RMB 13.9 million from exits in company and fund investments during the reporting period, compared to RMB 69.3 million in the same period last year[83]. Regulatory and Compliance Risks - The company must adapt to regulatory updates; failure to do so may negatively affect its operations and financial performance[118]. - The company emphasizes the importance of compliance with current and future laws, regulations, and industry standards, as failure to do so could significantly impact its business, financial condition, and operating performance[121]. - The company requires multiple regulatory approvals, licenses, and certifications to operate, and failure to obtain or renew these could lead to severe operational disruptions and financial impacts[122]. - Increased competition in the global clinical contract research market poses risks to the company's business and profitability[119]. Stock Options and Incentive Plans - The company has a stock incentive plan that allows for the issuance of stock options, with a total of 16.5 million options remaining unexercised as of the reporting date[137]. - The total number of shares available for issuance under the 2018 stock incentive plan is 85,823,591 shares, representing 4.2% of the total shares issued as of the report date[143]. - The total expense recognized for stock options granted under the 2018 Share Incentive Plan during the reporting period is approximately $1,045,000[151]. - The maximum number of shares available for grant under the 2021 Share Incentive Plan is 204,605,091 shares, representing 10% of the issued share capital at the time of adoption[154]. Challenges and Future Outlook - The company faces risks from potential natural disasters, pandemics, and other emergencies that could adversely affect operations, financial status, and performance[116]. - A decline in demand for biopharmaceutical research services could significantly impact the company's business, financial condition, and future prospects[117]. - The company anticipates continued business growth, necessitating effective management of expansion and strategic execution to avoid adverse impacts on financial performance[120]. - The company acknowledges the risk of talent loss, particularly among directors and senior management, which could disrupt business operations and growth[127].

Market Overview - On September 24, the medical services sector declined by 2.01%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Bid Medicine (688073) saw a closing price of 74.63, with a gain of 5.74% and a trading volume of 13,300 hands, totaling a transaction value of 98.38 million [1] - Tiger Medical (300347) closed at 61.00, up 5.54%, with a trading volume of 150,500 hands and a transaction value of 908 million [1] - Guangzheng Eye Hospital (002524) closed at 4.23, up 4.44%, with a trading volume of 189,200 hands and a transaction value of 78.72 million [1] - Nanmo Biology (688265) closed at 52.35, down 1.75%, with a trading volume of 11,300 hands and a transaction value of 59.06 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 318 million from institutional investors and 117 million from retail investors, while retail investors saw a net inflow of 434 million [2][3] - Tiger Medical (300347) had a net inflow of 10.8 million from institutional investors but a net outflow of 9.19 million from retail investors [3] - Eye Care (300015) recorded a net inflow of 37.33 million from institutional investors, while retail investors had a net outflow of 41.60 million [3]

Group 1 - The core viewpoint of the news is that Tiger Med has seen a significant increase in its stock price, rising by 5.17% to reach 60.79 CNY per share, with a total market capitalization of 52.342 billion CNY [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering a range of services from Phase I to IV clinical trials [1] - The company's main revenue sources include clinical trial-related services and laboratory services, accounting for 52.60%, clinical trial technical services at 45.21%, and other supplementary services at 2.19% [1] Group 2 - Morgan Fund has a significant holding in Tiger Med, with the Morgan CSI Innovative Drug Industry ETF (560900) reducing its stake by 3,000 shares in the second quarter, now holding 18,100 shares, which represents 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million CNY and has achieved a year-to-date return of 36.18%, ranking 1270 out of 4220 in its category [2] - The fund manager, Mao Shichao, has been in charge for 5 years and 140 days, with the best fund return during his tenure being 56.22% and the worst being -24.75% [3]